Accelerating Clinical Trial Success

Intelligence, technology, and expertise

What We Do

We provide technology, insights, and expertise that dramatically improve clinical trial success for all stakeholders—from design and feasibility to matching patients. Powered by a vast data consortium, an advanced enablement platform and deep insights, we believe that no time can be wasted in advancing the ability to bring promising and lasting solutions to critical illnesses. Our expert team is passionate about delivering solutions to use when life depends on it and helping improve the standard of care for patients everywhere.

EMPOWERING CLINICAL RESEARCH

Identifying high-potential clinical trial sites, screening for patients and finding the best trials are critical, yet arduous tasks. **We help clinicians and healthcare providers open the right trials, conduct more efficient patient screening and find the best clinical trials for patients.**

- Open more of the right clinical trials at your site
- Increase the accuracy of forecasting enrollment volume and timelines
- Accelerate patient recruitment and accrual rates
- Increase collaboration with industry sponsors and peers
- Close gaps between patient populations and your portfolio of clinical trials

Our Capabilities

- Advanced technology platform to accelerate clinical trials execution
- Patient matching to the biomarker level, substantially reducing the number of false positives
- Real-world evidence, in real-time, to quickly identify eligible patients
- Large Real World Data asset
- A watch list of patients who become eligible for trials
- Analytics able to predict patients about to fail a line of therapy
- Applications to facilitate collaboration between CROs and Providers
- Efficient trial site identification and selection
- Dynamic protocol feasibility

inteliquet

Inteliquet Consortium

3.8+ million	725,000+	11.7 million
patients	cancer patients	treatment details

Our vast data consortium allows access to Rx, therapies, Labs, molecular biomarkers, visit data, diagnoses, histology, outcomes, etc.

- Comprises leading oncology institutions across the nation, including community oncology practices and hospitals, integrated delivery networks and academic medical centers
- On track to reach more than 1 million cancer patients in 2019
- Allows comparisons of your patient population to aggregate metrics across the entire consortium for diagnoses, treatment pathways, molecular diagnostics, and outcomes
- A significant volume of clinical trials directly from our partners
- Allows multiple IT systems integration in weeks, speeding the access to new trials and related revenue

Patients First

We believe that every patient deserves access to a clinical trial. Clinical trials have the potential to save and extend lives, improve the standard of care, and ultimately find lasting solutions for cancer and other critical diseases. That's what drives us—every day we help ensure no patient goes without access to a clinical trial thus accelerating the availability of promising new treatments.

Leading Clinical Trial Innovation

An aggressive innovator with 20 approved claims of invention and more in the works

We develop valuable intellectual property (IP), including a metadata-driven methodology for extracting data from disparate electronic systems and standardizing the data into a repository—dramatically improving user experience for searching, reporting and analyzing patient data. Our approach enables connectivity to new sources of health care data in days and weeks—as opposed to today's standard of several months.

Our IP protection strategy is to aggressively pursue patents and maintain trade secrets during pre-patent research and development. We have multiple patents in progress in disease progression prediction, real-world evidence for improving treatment pathways, and developing algorithms for structured data extraction from free-text clinical notes.

Scientific Advisory Board

Barbara McAneny, MD, ASCO, MACP
President, American Medical Association (AMA)

Daniel D. Von Hoff, MD, FACP
Physician in Chief, Distinguished Professor of the Translational Research Division at TGen (Translational Genomics Research Institute)

Paul A. Bunn, Jr., MD
Distinguished Professor of Medicine and the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine

Noah M. Hahn, MD
Associate Professor of Medicine at the Department of Oncology and the Department of Urology at Johns Hopkins University School of Medicine

Stanley R. Hamilton, MD, FACP, AGAF
Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC)

W Jeff Edenfield, MD
Greenville Health System Institute for Translational Oncology Research

Contact us
info@inteliquet.com • inteliquet.com

inteliquet